Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 8/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | PKLR | P30613 | 2/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107793 | 0.87 | KIT (0.49) | LMNAPKMGAAKMT2AMEN1 | |
| SCHEMBL13248894 | 0.87 | KIT (0.47) | LMNATHRBGAAKMT2AMEN1 | |
| SCHEMBL13248887 | 0.87 | KMT2A (0.56) | GAAKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL13248893 | 0.86 | KMT2A (0.45) | LMNATHRBTP53PKMGAA | |
| SCHEMBL4661391 | 0.86 | ALDH1A1 (0.46) | LMNAPKMGAAKMT2AMEN1 | |
| SCHEMBL13248890 | 0.86 | KMT2A (0.50) | LMNAPKMGAAKMT2AMEN1 | |
| SCHEMBL13248881 | 0.86 | KIT (0.48) | LMNATP53GAAKMT2AMEN1 | |
| SCHEMBL13248884 | 0.85 | KIT (0.49) | LMNATHRBTP53PKMGAA | |
| SCHEMBL13248896 | 0.85 | ALDH1A1 (0.47) | LMNAGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL13248872 | 0.85 | GAA (0.57) | LMNAPKMGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| EP-1919890-A1 | PYRAZOLONE DERIVATIVES FOR THE TREATMENT OF TUBERCULOSIS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007020426-A1 | PYRAZOLONE DERIVATIVES FOR THE TREATMENT OF TUBERCULOSIS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | TREH, TYMP, EPX | LMNA 1808/4885THRB 311/4885TP53 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.